

Michal Gniot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6001367/publications.pdf>

Version: 2024-02-01

20
papers

199
citations

1163117

8
h-index

1058476

14
g-index

26
all docs

26
docs citations

26
times ranked

359
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. <i>Leukemia</i> , 2016, 30, 1844-1852.	7.2	51
2	Variant-specific discrepancy when quantitating <i>BCR-ABL1</i> e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay. <i>European Journal of Haematology</i> , 2019, 103, 26-34.	2.2	26
3	A multicenter prospective study on efficacy and safety of imatinib generics: A report from Polish Adult Leukemia Group imatinib generics registry. <i>American Journal of Hematology</i> , 2017, 92, E125-E128.	4.1	24
4	Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene. <i>Journal of Applied Genetics</i> , 2008, 49, 201-203.	1.9	22
5	Esterase D and gamma 1 actin level might predict results of induction therapy in patients with acute myeloid leukemia without and with maturation. <i>Medical Oncology</i> , 2013, 30, 725.	2.5	17
6	Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome. <i>Annals of Hematology</i> , 2015, 94, 1891-1897.	1.8	14
7	Coexistence of <i>JAK2</i> or <i>CALR</i> mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. <i>International Journal of Laboratory Hematology</i> , 2018, 40, 366-371.	1.3	11
8	Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. <i>Leukemia</i> , 2022, 36, 1834-1842.	7.2	10
9	Clonal chromosomal aberrations in Philadelphia negative cells such as monosomy 7 and trisomy 8 may persist for years with no impact on the long term outcome in patients with chronic myeloid leukemia. <i>Cancer Genetics</i> , 2017, 216-217, 1-9.	0.4	8
10	Germline missense NF1 mutation in an elderly patient with a blastic plasmacytoid dendritic cell neoplasm. <i>International Journal of Hematology</i> , 2019, 110, 102-106.	1.6	5
11	Megakaryocytic blast crisis in a chronic myeloid leukemia patient with a rare variant of Philadelphia rearrangement t(9;22;22) and a constitutional translocation t(3;7). <i>Cancer Genetics and Cytogenetics</i> , 2010, 199, 45-47.	1.0	2
12	K356dup an in-frame insertion in the <i>BCR-ABL</i> gene in an imatinib-resistant chronic myeloid leukemia. <i>International Journal of Laboratory Hematology</i> , 2012, 34, e3-6.	1.3	2
13	Transient presence of clonal chromosomal aberrations in Ph-negative cells in patients with chronic myeloid leukemia remaining in deep molecular response on tyrosine kinase inhibitor treatment. <i>Cancer Genetics</i> , 2014, 207, 503-510.	0.4	2
14	B-Cell Chronic Lymphocytic Leukemia with 11q22.3 Rearrangement in Patient with Chronic Myeloid Leukemia Treated with Imatinib. <i>Case Reports in Medicine</i> , 2016, 2016, 1-6.	0.7	2
15	Characterization and significance of the Philadelphia negative/BCR-ABL1 positive rearrangement or masked Philadelphia translocation in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single-center study. <i>Leukemia and Lymphoma</i> , 2020, 61, 189-193.	1.3	1
16	G ₁ ™boka odpowiedź molekularna po podaniu dazatynibu w 3. linii terapii u chorego na przewlekłą... białaczkę szpikową... w fazie przewlekłej. <i>Hematologia</i> , 2015, 6, 213-217.	0.0	1
17	Validation of HER2 Status in Whole Genome Sequencing Data of Breast Cancers with the Ploidy-Corrected Copy Number Approach. <i>Molecular Diagnosis and Therapy</i> , 2022, 26, 105-116.	3.8	1
18	Bortezomib has little ex vivo activity in chronic myeloid leukemia: individual tumor response testing comparative study in acute and chronic myeloid leukemia. <i>Wspolczesna Onkologia</i> , 2012, 3, 210-214.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Potential Leukemic Cells Engraftment After Hematopoietic Stem Cell Transplantation From Unrelated Donors With Undiagnosed Chronic Leukemia. <i>Transplantation Proceedings</i> , 2018, 50, 3789-3796.	0.6	0
20	Limfocytoza CD4+CD8+ oraz wysiÅ™ki osierdziowy i opÅ„ucnowy u chorego na przewlekÅ„... biaÅ„aczkÅ™ szpikowÅ„... w fazie przewlekÅ„ej leczonego dazatynibem z powodu niepowodzenia terapii imatynibem. <i>Hematologia</i> , 2015, 6, 301-307.	0.0	0